SEC Info - Parallax Health Sciences, Inc. - ‘10-Q/A’ for 9/30/18

SEC Info℠

Home

Help

Please Sign In

Parallax Health Sciences, Inc. – ‘10-Q/A’ for 9/30/18 – ‘EX-100.CAL’

On: Thursday, 11/15/18, at 8:35pm ET · As of: 11/16/18 · For: 9/30/18 · Accession #: 1388410-18-84 · File #: 0-52534

  As Of               Filer                 Filing    For·On·As Docs:Size

11/16/18  Parallax Health Sciences, Inc.    10-Q/A      9/30/18  107:5.9M

Amendment to Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q/A      Quarterly Report (XBRL)                             HTML     47K 
 8: R1          Document and Entity Information                     HTML     59K 
 9: R2          Consolidated Balance Sheets                         HTML    115K 
10: R3          Consolidated Balance Sheets - Parenthetical         HTML     44K 
11: R4          Consolidated Statements of Operations               HTML     88K 
12: R5          Consolidated Statements of Cash Flows               HTML    132K 
13: R6          Overview and Nature of Business                     HTML     59K 
14: R7          Significant Accounting Policies                     HTML     65K 
15: R8          Accounts Receivable, Net                            HTML     42K 
16: R9          Intangible Assets                                   HTML     44K 
17: R10         Accounts Payable and Accrued Expenses               HTML     45K 
18: R11         Notes and Loans Payable                             HTML     93K 
19: R12         Related Party Transactions                          HTML     67K 
20: R13         Commitments And Contingencies                       HTML     39K 
21: R14         Convertible Preferred Stock                         HTML     36K 
22: R15         Common Stock                                        HTML     43K 
23: R16         Warrants And Options                                HTML    128K 
24: R17         Leases                                              HTML     33K 
25: R18         Income Taxes                                        HTML     72K 
26: R19         Change in Estimate and Correction of Error          HTML    134K 
27: R20         Discontinued Operations                             HTML     77K 
28: R21         Segment Reporting                                   HTML     81K 
29: R22         Legal Matters                                       HTML     53K 
30: R23         Subsequent Events                                   HTML     33K 
31: R24         Significant Accounting Policies (Policies)          HTML    117K 
32: R25         Significant Accounting Policies: Accounts           HTML     39K 
                Receivable: Allowance for Doubtful Accounts                      
                (Tables)                                                         
33: R26         Accounts Receivable, Net: Schedule of Accounts      HTML     38K 
                Receivable, Net (Tables)                                         
34: R27         Intangible Assets: Schedule of Intangible Assets,   HTML     44K 
                Net (Tables)                                                     
35: R28         Accounts Payable and Accrued Expenses: Accounts     HTML     44K 
                Payable and Accrued Expenses (Tables)                            
36: R29         Notes and Loans Payable: Schedule of Notes and      HTML     60K 
                Loans Payable (Tables)                                           
37: R30         Notes and Loans Payable: Non-Related Party          HTML     51K 
                Convertible Notes Payable (Tables)                               
38: R31         Related Party Transactions: Summary (Tables)        HTML     43K 
39: R32         Related Party Transactions: Related Party           HTML     46K 
                Convertible Debt, By Related Party (Tables)                      
40: R33         Warrants And Options: Warrants Outstanding          HTML     73K 
                (Tables)                                                         
41: R34         Warrants And Options: Warrant Activity (Tables)     HTML     39K 
42: R35         Warrants And Options: Options Outstanding (Tables)  HTML     66K 
43: R36         Warrants And Options: Options Activity (Tables)     HTML     39K 
44: R37         Income Taxes: Schedule of Components of Income Tax  HTML     61K 
                Expense (Benefit) (Tables)                                       
45: R38         Income Taxes: Schedule of Deferred Tax Asset        HTML     44K 
                (Tables)                                                         
46: R39         Change in Estimate and Correction of Error:         HTML     67K 
                Schedule of Effects of Change in Estimate (Tables)               
47: R40         Change in Estimate and Correction of Error:         HTML     98K 
                Schedule of Error Corrections (Tables)                           
48: R41         Discontinued Operations: Schedule of Discontinued   HTML     71K 
                Operations, Balance Sheet (Tables)                               
49: R42         Discontinued Operations: Schedule of Discontinued   HTML     40K 
                Operations, Income Statement (Tables)                            
50: R43         Segment Reporting: Schedule of Segment Reporting    HTML     82K 
                Information, by Segment (Tables)                                 
51: R44         Overview and Nature of Business: Deconsolidation    HTML     32K 
                (Details)                                                        
52: R45         Overview and Nature of Business: Going Concern      HTML     33K 
                (Details)                                                        
53: R46         Significant Accounting Policies: Accounts           HTML     38K 
                Receivable: Allowance for Doubtful Accounts                      
                (Details)                                                        
54: R47         Significant Accounting Policies: Accounts           HTML     35K 
                Receivable (Details)                                             
55: R48         Significant Accounting Policies: Property and       HTML     37K 
                Equipment: Useful Life (Details)                                 
56: R49         Accounts Receivable, Net: Schedule of Accounts      HTML     40K 
                Receivable, Net (Details)                                        
57: R50         Accounts Receivable, Net: Allowance For Doubtful    HTML     35K 
                Accounts (Details)                                               
58: R51         Intangible Assets: Schedule of Intangible Assets,   HTML     51K 
                Net (Details)                                                    
59: R52         Intangible Assets: Amortization Expense (Details)   HTML     33K 
60: R53         Accounts Payable and Accrued Expenses: Summary      HTML     49K 
                (Details)                                                        
61: R54         Accounts Payable and Accrued Expenses: Payroll      HTML     34K 
                Taxes Payable (Details)                                          
62: R55         Accounts Payable and Accrued Expenses (Details)     HTML     33K 
63: R56         Notes and Loans Payable: Summary (Details)          HTML     64K 
64: R57         Notes and Loans Payable: Notes Payable-Current      HTML     97K 
                Activity (Details)                                               
65: R58         Notes and Loans Payable: Short-Term (Details)       HTML     39K 
66: R59         Notes and Loans Payable: Long-Term (Details)        HTML     62K 
67: R60         Notes and Loans Payable: Future Maturities          HTML     38K 
                (Details)                                                        
68: R61         Notes and Loans Payable: Accrued Interest           HTML     36K 
                (Details)                                                        
69: R62         Related Party Transactions: Summary (Details)       HTML     46K 
70: R63         Related Party Transactions: Convertible Debt        HTML     45K 
                (Details)                                                        
71: R64         Related Party Transactions: Current Activity        HTML     54K 
                (Details)                                                        
72: R65         Related Party Transactions: Summary Totals          HTML     39K 
                (Details)                                                        
73: R66         Related Party Transactions: Recent Agreements       HTML     62K 
                (Details)                                                        
74: R67         Related Party Transactions: Preferred Stock         HTML     43K 
                Issuance (Details)                                               
75: R68         Related Party Transactions: Accrued Interest        HTML     34K 
                (Details)                                                        
76: R69         Commitments And Contingencies: Promissory Note      HTML     46K 
                (Details)                                                        
77: R70         Commitments And Contingencies: Description          HTML     34K 
                (Details)                                                        
78: R71         Commitments And Contingencies (Details)             HTML     35K 
79: R72         Commitments And Contingencies: Revenue Share &      HTML     37K 
                Royalties (Details)                                              
80: R73         Convertible Preferred Stock: Authorized and Issued  HTML     37K 
                Shares (Details)                                                 
81: R74         Convertible Preferred Stock: Series C Convertible   HTML     46K 
                Preferred Offering Details (Details)                             
82: R75         Convertible Preferred Stock: Current Issuances      HTML     40K 
                (Details)                                                        
83: R76         Common Stock: Authorized and Issued Shares          HTML     38K 
                (Details)                                                        
84: R77         Common Stock: Current Issuances (Details)           HTML     96K 
85: R78         Common Stock: Deferred Stock Compensation           HTML     39K 
                (Details)                                                        
86: R79         Warrants And Options: Outstanding (Details)         HTML     35K 
87: R80         Warrants And Options: Warrants, Current Period      HTML     39K 
                Grants (Details)                                                 
88: R81         Warrants And Options: Schedule of Warrants          HTML     83K 
                Outstanding (Details)                                            
89: R82         Warrants And Options: Warrant Rollforward           HTML     48K 
                (Details)                                                        
90: R83         Warrants And Options: Options, Current Period       HTML     61K 
                Grants (Details)                                                 
91: R84         Warrants And Options: Options Outstanding           HTML     85K 
                (Details)                                                        
92: R85         Warrants And Options: Options Summary (Details)     HTML     39K 
93: R86         Warrants And Options: Deferred Stock Option         HTML     38K 
                Compensation (Details)                                           
94: R87         Leases (Details)                                    HTML     33K 
95: R88         Leases: Rent Expense (Details)                      HTML     32K 
96: R89         Income Taxes: Components of Income Tax Expense      HTML     68K 
                (Benefit) (Details)                                              
97: R90         Income Taxes: Deferred Tax Asset (Details)          HTML     48K 
98: R91         Income Taxes: Tax Years Open to Examination         HTML     32K 
                (Details)                                                        
99: R92         Change in Estimate and Correction of Error:         HTML     66K 
                Summary of Effects of Change in Estimate (Details)               
100: R93         Change in Estimate and Correction of Error:         HTML     34K  
                Correction of Error (Details)                                    
101: R94         Change in Estimate and Correction of Error:         HTML    101K  
                Summary of Effects of Error Corrections (Details)                
102: R95         Discontinued Operations: Schedule of Discontinued   HTML     88K  
                Operations, Balance Sheet (Details)                              
103: R96         Discontinued Operations: Schedule of Discontinued   HTML     54K  
                Operations, Income Statement (Details)                           
104: R97         Segment Reporting: Schedule of Segment Reporting    HTML     67K  
                Information, by Segment (Details)                                
106: XML         IDEA XML File -- Filing Summary                      XML    210K  
105: EXCEL       IDEA Workbook of Financial Reports                  XLSX    111K  
 4: EX-100.INS  XBRL Instance -- prlx-20180930                       XML   2.03M 
 2: EX-100.CAL  XBRL Calculations -- prlx-20180930_cal               XML     76K 
 3: EX-100.DEF  XBRL Definitions -- prlx-20180930_def                XML    611K 
 5: EX-100.LAB  XBRL Labels -- prlx-20180930_lab                     XML   1.32M 
 6: EX-100.PRE  XBRL Presentations -- prlx-20180930_pre              XML    968K 
 7: EX-100.SCH  XBRL Schema -- prlx-20180930                         XSD    327K 
107: ZIP         XBRL Zipped Folder -- 0001388410-18-000084-xbrl      Zip    169K

‘EX-100.CAL’ — XBRL Calculations — prlx-20180930_cal

This Exhibit is an XBRL XML File.

<?xml version="1.0" encoding="windows-1252"?>

<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:fil="http://Parallaxhealthsciences.com/20180930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance">

<link:roleRef roleURI="http://Parallaxhealthsciences.com/20180930/role/idr_CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="prlx-20180930.xsd#idr_CONSOLIDATEDBALANCESHEETS"/>

<link:calculationLink xlink:type="extended" xlink:role="http://Parallaxhealthsciences.com/20180930/role/idr_CONSOLIDATEDBALANCESHEETS">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNet" use="optional" order="2.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="prlx-20180930.xsd#fil_CurrentAssetsHeldForSale" xlink:label="fil_CurrentAssetsHeldForSale"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="fil_CurrentAssetsHeldForSale" use="optional" order="3.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" use="optional" order="2.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" use="optional" order="3.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="prlx-20180930.xsd#fil_NoncurrentAssetsHeldForSale" xlink:label="fil_NoncurrentAssetsHeldForSale"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="fil_NoncurrentAssetsHeldForSale" use="optional" order="4.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent" use="optional" order="2.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent" use="optional" order="3.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>

<link:loc xlink:type="locator" xlink:href="prlx-20180930.xsd#fil_LicenseFeesPayableNetOfUnamortizedDiscount" xlink:label="fil_LicenseFeesPayableNetOfUnamortizedDiscount"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="fil_LicenseFeesPayableNetOfUnamortizedDiscount" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" use="optional" order="2.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_UnsecuredLongTermDebt" use="optional" order="3.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent" use="optional" order="4.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" use="optional" order="5.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_SecuredLongTermDebt" use="optional" order="6.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" use="optional" order="2.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" use="optional" order="2.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalPreferredStock" use="optional" order="3.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="4.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" use="optional" order="5.0" weight="-1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="6.0" weight="1.0"/>

</link:calculationLink>

<link:roleRef roleURI="http://Parallaxhealthsciences.com/20180930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="prlx-20180930.xsd#idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>

<link:calculationLink xlink:type="extended" xlink:role="http://Parallaxhealthsciences.com/20180930/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONS">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" use="optional" order="2.0" weight="-1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" use="optional" order="2.0" weight="-1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" use="optional" order="2.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnSaleOfBusiness" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="2.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" use="optional" order="3.0" weight="-1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseDebt" use="optional" order="4.0" weight="-1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="1.0" weight="1.0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>

<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" use="optional" order="2.0" weight="1.0"/>

</link:calculationLink>

</link:linkbase>

↑Top

Filing Submission 0001388410-18-000084 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Parallax Health Sciences, Inc. – ‘10-Q/A’ for 9/30/18 – ‘EX-100.CAL’

On: Thursday, 11/15/18, at 8:35pm ET · As of: 11/16/18 · For: 9/30/18 · Accession #: 1388410-18-84 · File #: 0-52534

Previous ‘10-Q’: ‘10-Q’ on 11/15/18 for 9/30/18 · Next: ‘10-Q/A’ on 3/11/19 for 9/30/18 · Latest: ‘10-Q/A’ on 12/13/19 for 9/30/19

Amendment to Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘EX-100.CAL’ — XBRL Calculations — prlx-20180930_cal

This Exhibit is an XBRL XML File.

Amendment to Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents